Company ProfilePremium

Ahn-Gook Pharmaceutical Co., Ltd.

Company Profile Analysis

Ticker: 001540.KQ안국약품 주식회사

ESOMAR 23 Corporate BadgeISO Certifications Badge
Ahn-Gook Pharmaceutical Co., Ltd. - Company showcase

Year Founded & Workforce

1959

424 Employees

Ahn-Gook Pharmaceutical Co., Ltd. logo

Ahn-Gook Pharmaceutical Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Ahn-Gook Pharmaceutical Co., Ltd. Overview

Ahn-Gook Pharmaceutical is a family-controlled, mid-sized Korean prescription-drug maker that has rebuilt itself since 2021 around domestic chronic-disease combination products. It is founder-led in origin, has had a professional CEO since 2022 and reports roughly KRW 307bn of consolidated FY2025 revenue. Its historic franchise is Synatura (시네츄라), an internally developed botanical antitussive/expectorant syrup that peaked with the COVID-19 respiratory cycle. The growth engine has since shifted to cardiovascular and metabolic tablets, chiefly Fevarozet (pitavastatin/ezetimibe). Fevarozet became the company's largest product in 2026 and also anchors a contract-manufacturing (CMO) business that supplies most competing pitavastatin/ezetimibe generics. A consumer health-and-beauty (H&B) channel pushing health functional foods through Daiso, Olive Young and its own online mall now contributes roughly 9% of sales. Management targets KRW 500bn of revenue and a top-10 UBIST prescription ranking by 2030. A long-running criminal rebate case against the controlling shareholder, plus a 2026 GMP-related manufacturing suspension, are the principal governance and operational overhangs. Valuation is deep-value: below book, single-digit P/E, and a high dividend yield.


What the company does

Ahn-Gook researches, manufactures and sells finished-dose pharmaceuticals in South Korea. Most revenue comes from prescription (ETC) drugs dispensed through the national health insurance reimbursement system. Over-the-counter (OTC) drugs, health functional foods (HFF) and contract manufacturing for third-party pharma companies supplement this. Its own descriptions in DART and on its website emphasise respiratory and cardiovascular therapeutics, improved formulations (개량신약, "incrementally modified drugs") and a "total healthcare" ambition. Aggregator profiles derived from company material describe it as protecting public health since 1959 and as releasing improved new drugs built on internal R&D capability (Fundable/LinkedIn description). They also note a strong focus on respiratory and cardiovascular treatments (financialfilings.com company summary).

Revenue model

Revenue streamDescriptionDisclosed weight
Own-brand prescription products (제품)Internally developed or registered generics and combinations: Fevarozet, Synatura, Levotension family, lipid combinationsMajority. Butler.works (Q2 2026) therapeutic split: cardiovascular 47%, respiratory 16%, gastrointestinal 10%, other pharmaceuticals 17%
In-licensed / merchandise products (상품)Products licensed from domestic and foreign companies; Widaplik (George Medicines) is the most recent—
Health functional foods & H&B (건강기능식품 등)Stick-type supplements and related consumer products via Daiso, Olive Young and own mall≈9% (Q2 2026 basis, Butler.works)
Contract manufacturing (수탁 생산)Manufactures pitavastatin/ezetimibe combinations for Daewon, Boryung, Dongkwang, Hanlim and othersNot separately disclosed; Dailypharm (Feb 2026) says Ahn-Gook manufactures every pitavastatin/ezetimibe combination on the market except JW's Livalozet
Licensing / royaltyNo material out-licensing income disclosedNegligible

The model is product-led, with no subscription or service income. The pharmaceutical P&L is typical of a Korean generic/combination specialist: modest gross margins, heavy sales and marketing spend through in-house reps and contract sales organisations (CSOs), and low R&D intensity. Management has been reducing CSO exposure in channels with weak prescription verification. In September 2024 the company told CSOs to stop new long-term-care hospital accounts after prescription documentation repeatedly covered less than 80% of shipped volume (Dealsite, 10 Oct 2024).

Value-chain position

Ahn-Gook is vertically integrated from formulation development through finished-dose manufacturing to domestic marketing. It runs its own finished-dose plant in the Hyangnam pharmaceutical complex, Hwaseong. It buys active pharmaceutical ingredients (APIs) from third parties, and no in-house API synthesis is disclosed. In the pitavastatin/ezetimibe sub-segment it is both brand marketer and toll manufacturer for competitors, an unusual position that lets it earn on rivals' volume growth.

Customer types and end-markets

Prescribers and dispensers: clinics (의원) and hospitals, especially internal medicine, family medicine, cardiology, ENT and paediatrics. Reimbursement is via the National Health Insurance Service, under price regulation by HIRA and the Ministry of Health and Welfare.

Pharmaceutical wholesalers: physical distribution to pharmacies and hospitals.

Retail consumers: OTC drugs through pharmacies; HFF through Daiso, Olive Young, the company's own mall and pharmacies.

Pharma companies (B2B): contract manufacturing customers.

Geography: overwhelmingly domestic. Exports exist but are not quantified, and Dealsite reported a declining export trend in 2024.

Independent characterisation

Ahn-Gook is best understood as a domestic chronic-care combination-product franchise layered on a declining seasonal respiratory brand, with an emerging consumer channel. The 2022–2026 growth (consolidated revenue +114% over five years, per Dailypharm, Feb 2026) came from three things. First, the pandemic and endemic respiratory cycle boosted Synatura. Second, a well-timed patent challenge and fast-follower launch in pitavastatin/ezetimibe gave the company the market's leading generic position. Third, cost discipline produced operating leverage that only became visible in 2026 (Q1 2026 operating margin 16.2%). The company is not a novel-drug innovator. Its R&D is formulation-led, and its pipeline bets are pursued mainly through affiliates and financial investments (MustBio, the Mirae Asset new-growth fund) rather than internal first-in-class programmes.

Strategy

Stated corporate strategy

The strategic framework is "AHN-GOOK 2030 NEW VISION," declared in 2020. It has three pillars (Dealsite, 25 Apr 2024):

  1. Business diversification through total healthcare.

  2. Launch of differentiated improved new drugs (개량신약).

  3. Export expansion.

The company presents the 2024 Gwacheon relocation as the platform for achieving the 2030 vision and for becoming a "K-Health" company (Dailypharm, 30 Apr 2024).

CEO Park In-cheol updated the targets in January 2026 (Dailypharm DP interview, 19 Jan 2026). The themes he set out were:

Revenue of KRW 500bn by 2030: and a top-10 ranking by UBIST outpatient prescription value, with healthcare "plus-alpha" businesses as upside.

Two-track R&D: in-house development accelerated after the Gwacheon R&D Center opened, plus external collaboration.

  • Expanded business development (BD), open innovation and pipeline strengthening.

  • Concentration on the cardiovascular and respiratory axes, with collaboration-based investments in bio and medical devices.

  • Explicit planning for drug-price cuts and tighter regulation.

An August 2025 Dealsite article quoted a target of KRW 500bn by 2027. That conflicts with the 2030 horizon in the CEO's January 2026 interview; the CEO's statement is treated as authoritative.

Strategic initiatives (last 24 months)

InitiativeDateDescriptionStatus / targetSource
Co-CEO structure, sales & marketing reinforcementJan 2025Owner + professional CEO modelImplementedDailypharm
R&D and production reorganisationFeb 2025Specialisation of research and production divisionsImplementedDailypharm
Organisational culture rebuilding & AI-based work innovation2,025Internal transformation programmeOngoingDailypharm related headline
Shareholder return enhancementFeb–Oct 2025DPS doubled; capital reserve converted to retained earningsImplemented; FY2025 dividend yield ~7%Medical Times; Dailypharm
New-growth venture fundOct 2025KRW 20bn fund with Mirae Asset Capital (Ahn-Gook 65%) targeting bio and medical devicesCommitted to 2029Digital Today; Dailypharm
Medical-materials entry2025 (date not confirmed)MOU with SOFNT (nanofibre materials, founded 2020); the company's first venture beyond pharma/bioMOU stageCB Insights news summary
H&B multichannel2025–2026HFF through Daiso, Olive Young, own mallContributing about 9% of revenueDailypharm, May 2026
Widaplik in-licensingMar 2026First-line triple hypertension combination; builds an initial-to-second-line combination ladderKorean trials and approval pendingDailypharm; NewDaily
Fevarozet low-dose line extensionApr 20261/10 mg approval; responds to the low-dose statin trendApprovedDailypharm, 22 Apr 2026
Hyangnam capacity expansionJul 2026KRW 48.48bn plant extensionCompletion end-2027 / Aug 2028Dailypharm
Dedicated liquid-formulation plantSep 2026Smart-factory oral-liquid plantTarget Oct 2027Medical Times
EHS certification maintenanceJun 2026ISO 14001 / ISO 45001 surveillance audits passed at all sitesMaintainedDailypharm

Medium-term financial targets and guidance

TargetValueHorizonSource
RevenueKRW 500bn2,030Dailypharm DP interview, Jan 2026
Industry rankTop 10 by UBIST outpatient prescriptions2,030Same
Margin / EPS / dividend guidance———

The company does not issue formal quarterly or annual guidance.

Products & Services

Organised by therapeutic class. Ahn-Gook does not publish product-level pricing; Korean reimbursed drug prices are set by HIRA and are not company pricing decisions.

Cardiovascular & metabolic (≈47% of revenue)

ProductComposition / descriptionKey specificationsTarget patient / prescriberLaunch / latest versionNotes & source
Fevarozet (페바로젯)Pitavastatin calcium + ezetimibe fixed-dose combinationStrengths 2/10 mg and 4/10 mg (Aug 2023); 1/10 mg approved Apr 2026. Proprietary small tablet (10 mm × 4.9 mm), about 46% smaller than the reference Livalozet. Phase 3 at 20 Korean sites showed ~57% LDL-C reduction at week 8 with no observed glycaemic-marker changesDyslipidaemia; primary care, cardiologyApproved May 2023; launched Aug 2023; low-dose 1/10 mg Apr 2026FY2025 sales KRW 29.1bn; monthly sales above KRW 3.4bn in Dec 2025; Dec-vs-Jan 2025 growth 118% vs 34% for Livalozet (Dailypharm, 5 Feb 2026; 22 Apr 2026)
Fevarozet CMO supplySame molecule manufactured for third partiesPartner brands include Tabarozet (Daewon), Elzerozet, Pizet, Starzet and products for Boryung, Dongkwang, HanlimB2B2023 onwardAhn-Gook makes all pitavastatin/ezetimibe combos except Livalozet (Dailypharm, Feb 2026)
Fevaro (페바로)Pitavastatin monotherapy—Dyslipidaemia—Part of lipid franchise (Dailypharm, Oct 2021)
Fevaro-F (페바로에프)Pitavastatin-based combination (second component not confirmed in sources reviewed)—Mixed dyslipidaemia—One of the "three lipid combinations" (Dailypharm, Feb 2025)
Shuvazet (슈바젯)Rosuvastatin + ezetimibe10/5, 10/10, 10/20 mgDyslipidaemiaApproved Oct 20163-month sales suspension Nov 2021–Jan 2022; H1 2021 Rx about KRW 2.4bn (Dailypharm, 22 Oct 2021)
Shustar (슈스타)Rosuvastatin monotherapy—Dyslipidaemia—Dailypharm, Oct 2021
Lipozet (리포젯)Statin + ezetimibe combination (statin not confirmed)—Dyslipidaemia—Dailypharm, Oct 2021
Levotension (레보텐션정) ("Revo Tension" in English listings)S-amlodipine (single-enantiomer calcium-channel blocker)Paediatric indication addedHypertensionpaediatric indication addedListed as flagship by Yahoo Finance/MarketInOut; Dailypharm related-news list
Levosartan family (레보살탄 계열)S-amlodipine + losartan-based combinations—Hypertension—Cited as a key tablet franchise (NewDaily, 15 May 2026)
Indapamide-based antihypertensive combinationsIndapamide fixed-dose combinations—Hypertension2025–2026NewDaily, 15 May 2026
Widaplik (위다플릭) (in-licensed, pre-launch)Telmisartan + amlodipine + indapamide, low-dose triple combination10/1.25/0.625 mg, 20/2.5/1.25 mg, 40/5/2.5 mg. First fixed-dose combination approved by the US FDA for initial (first-line) hypertension treatment; pivotal data published in The Lancet and JACCHypertension, first-lineKorean licence 12 Mar 2026; local trials and MFDS approval pendingExclusive Korean clinical, regulatory and commercial rights from George Medicines (Dailypharm, 12 Mar 2026)
Ahngook Vildagliptin 50 mg (안국빌다글립틴정)Vildagliptin (DPP-4 inhibitor) genericFirst-generic priority sales rightType 2 diabetesApproved Nov 2019; exclusivity 30 Aug 2021–29 May 2022Dailypharm, 12 Dec 2019
Avesmet (에이브스메트정)DPP-4 inhibitor + metformin combination—Type 2 diabetes2,022Jobplanet company history
Ateneel / Ateneel M (에이테넬정 / 에이테넬엠정)Teneligliptin (DPP-4) ± metformin—Type 2 diabetes2022 (per company history; month not confirmed)Jobplanet company history

Respiratory (≈16% of revenue)

ProductDescriptionKey specificationsTargetLaunchNotes & source
Synatura (시네츄라시럽)Internally developed botanical (natural-product) antitussive / expectorant syrupOral liquid; ivy-leaf and coptis-based botanical formulation (composition per company labelling; not re-verified here)Acute bronchitis / cough and sputum; ENT, paediatrics, internal medicineLaunch year not re-verified in this reviewFY2025 sales KRW 32.2bn (10.5% of revenue). About KRW 35bn in FY2022 (+100% YoY, Dailypharm column). Prescriptions fell in 2025 on the post-pandemic base effect. US licence (Gravity Bio) terminated pre-2019
Other respiratory liquidsLiquid formulations benefiting from rising demand———Management cites expanding liquid-product demand as the rationale for the new liquid plant (Dailypharm, May 2026; Medical Times, Sep 2026)

Gastrointestinal (≈10% of revenue)

Product-level detail for the digestive franchise is not disclosed in the sources reviewed. CB Insights describes a "digestive agent" as one of the company's recognised products.

Other pharmaceuticals (≈17% of revenue)

ProductDescriptionTargetLaunchSource
Amiga SR (에이미가서방정)Mirabegron extended-release genericOveractive bladderMay 2022Jobplanet company history
Tobicom-S (토비콤-에스)Soft capsule eye-health product (historic OTC brand)Eye fatigue / ophthalmic nutritionJan 1995Jobplanet; Morningstar profile notes the company is "famous for medicine for ophthalmology"
Ophthalmology line extensionsThe company announced entry into the ophthalmology businessOphthalmology—Dailypharm related-news list
Dry-eye treatment (co-development)Co-development agreement with Daewoo PharmDry eye disease—Jobplanet company history
Neurogate (뉴로게이트)Sales agreement with Salted (솔티드) for a digital/neuro product——Dailypharm related-news list
Vuno AI fundus screeningSupply agreement for Vuno's AI-based fundus examination solutionClinicsMar 2022Jobplanet company history
GenBody COVID-19 rapid antigen kitDistribution (historic)—Feb 2022Jobplanet company history
Legacy productsIntercal, Unol, Saerogenta cream, Clio syrup, Dacorin capsules, Tiston, Grandpase triple tablets, Silidu soft capsulesVarious1990sJobplanet company history

Health functional foods & H&B (≈9% of revenue)

OfferingDescriptionChannelStatusSource
Stick-type health functional foodsSingle-serve stick supplements; demand growth cited as a Q1 2026 driverDaiso, Olive Young, own online mall, pharmaciesExpanding 2025–2026Dailypharm, 14 May 2026
Daiso rangeLower-price, smaller-pack HFF lines; Ahn-Gook was reported in May 2025 to be negotiating entryDaisoEntered (2025–2026)NewDaily, 7 May 2025; Dailypharm, 14 May 2026

Contract manufacturing services

The Hyangnam plant provides toll manufacturing of pitavastatin/ezetimibe combinations for multiple Korean companies. The April 2026 low-dose approval is expected to lift both own-brand and contract revenue (Dailypharm, 22 Apr 2026). Contract-manufacturing revenue is not separately disclosed.

Financial Narrative

Basis: consolidated K-IFRS as transcribed by Butler.works from DART business reports unless stated. Units: KRW 100M. Blank = not publicly disclosed in sources reviewed.

Income statement

Margins derived from Butler.works revenue and profit figures. Revenue CAGR FY2021–FY2025 = 17.0% (derived). DPS: KRW 220 was the long-standing level, doubled to KRW 440 for FY2024 (Medical Times, 17 Oct 2025). FY2025 DPS is not confirmed in sources reviewed. Dailypharm (20 Mar 2026) reports that Ahn-Gook ranked first among 70 Korean pharma/bio companies by FY2025 market dividend yield at about 7%, implying a further DPS increase.

Quarterly trajectory (consolidated)

Sources: ETFshopping (DART quarterly filings); Dailypharm and Medical Times for Q1 2026. Q4 2025 values are derived as FY2025 minus 9M 2025. The implied Q4 2025 operating loss of about KRW 6.0bn suggests year-end charges such as inventory, bonus or R&D true-ups; the nature of these charges is not disclosed in sources reviewed.

H1 2026 vs H1 2025 (derived): revenue KRW 190.8bn vs KRW 152.6bn (+25.0%); operating income KRW 24.6bn vs KRW 10.8bn (+128%); net income KRW 21.0bn vs KRW 6.6bn. Trailing-twelve-month to Q2 2026 (derived): revenue ≈ KRW 345.1bn, operating income ≈ KRW 23.5bn, net income ≈ KRW 21.7bn.

Balance sheet

Sources: total assets at 31 Dec 2024 of KRW 302.54bn (Digital Today, citing the 31 Oct 2025 DART equity-acquisition filing); consolidated equity at 31 Dec 2025 of KRW 166.29bn (Dailypharm, 14 Jul 2026, citing the capex filing). MarketInOut (20 Aug 2026) reports debt/equity of 0.46 and interest coverage of 7.56x on a trailing basis. Butler.works' P/B of 0.74 at a KRW 132.5bn market cap implies book equity of about KRW 179bn at the latest reported date (derived).

Cash flow

Cash-flow statements are not transcribed in accessible sources. Known cash events: Daerim-dong HQ sale of KRW 22.0bn in 2024 (Dailypharm); KRW 13.0bn commitment to the Mirae Asset fund (staged to 30 Oct 2029); KRW 48.48bn Hyangnam expansion capex approved 14 Jul 2026, with stated periods to end-2027 (Dailypharm, 14 Jul 2026) and to end-Aug 2028 (Dailypharm, 28 Jul 2026), a discrepancy noted. No buyback authorisation was disclosed between 2022 and August 2025 (Dealsite, 20 Aug 2025: no treasury-share acquisitions or disposals in three years).

Ratios

FY2025 ROE derived as net income ÷ year-end consolidated equity (73 ÷ 1662.9). Trailing aggregator readings (MarketInOut, 20 Aug 2026): ROE 9.78%, ROA 5.26%, ROIC 7.67%, debt/equity 0.46, interest cover 7.56x, EBITDA (TTM) KRW 30.5bn, Piotroski F-score 8/9, Altman Z 2.63. Stockhub (Jul 2026): ROE 5.49%. Differences reflect different trailing windows.

Commentary on trends, inflections and drivers

Revenue. Consolidated revenue more than doubled from the FY2020 trough of KRW 143.4bn to KRW 306.9bn in FY2025, a 17.0% CAGR from FY2021. The growth came in two waves.

FY2021–FY2023 (respiratory wave): Synatura prescriptions surged through the pandemic and endemic flu/cold seasons. Respiratory reached a quarter of sales in H1 2022.

FY2024–FY2026 (cardiometabolic wave): Fevarozet launched in August 2023 and scaled to KRW 29.1bn in FY2025. Combined with Shuvazet and Fevaro-F, lipid combinations reached KRW 37.8bn of FY2024 prescriptions. This offset Synatura's 2025 normalisation. H1 2026 revenue grew 25% YoY, an acceleration from the 13–16% pace of FY2023–FY2025, with H&B as an incremental driver.

Profitability. For most of the period profitability was structurally thin. Operating margins of 2–5% in FY2022–FY2025 reflected a heavy CSO commission burden, rising cost of goods and inventory write-offs. FY2023's margin compression was attributed to a higher cost ratio, disposal of slow-moving inventory and higher sales-agency commissions on growing revenue (Dailypharm, 21 Feb 2024). The inflection came in Q1 2026: a 16.2% operating margin, against 7.7% a year earlier. Management credits sustained cost management and the shift in mix toward self-manufactured Fevarozet (Medical Times, 15 May 2026). NewDaily described Q1 2026 profitability as the best operating margin in about ten years. Q2 2026 eased to 9.4%, which still more than doubled the margin of Q2 2025.

Net income volatility. FY2024 net income of KRW 16.3bn was inflated by the Daerim-dong HQ disposal gain. FY2025's decline to KRW 7.3bn is a base effect, not deterioration (Medical Times, 19 Mar 2026). FY2023 net income of only KRW 1.0bn reflected weak operating profit and non-operating items.

Balance sheet and capital allocation. The HQ sale and the 2026 earnings step-up created headroom to commit almost KRW 50bn to plant expansion. That commitment equals 29% of equity, which is large relative to the company's size. The company has done this while doubling the dividend and expanding distributable reserves. Treasury shares (12.86%) are unused. Leverage appears moderate (aggregator debt/equity 0.46), but gross debt and cash balances are not disclosed in accessible sources. Analysts should obtain them from the DART filings before drawing liquidity conclusions.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Therapeutic Class Details

Therapeutic classMain contentsShare of revenue (%), Q2 2026 basis

Cardiovascular agents (순환기용제)

Fevarozet, Fevaro, Shuvazet, Fevaro-F, Levotension, Levosartan family, Widaplik (pre-launch)

47

Other pharmaceuticals (기타의약품)

Diabetes (vildagliptin, teneligliptin combinations), urology, ophthalmology and others

17

Respiratory agents (호흡기용제)

Synatura syrup and other respiratory products

16

Gastrointestinal agents (소화기계용제)

Digestive products (product-level detail not disclosed)

10

Health functional foods etc. (건강기능식품 등)

Stick-type supplements, H&B products

9

Revenue by Segment (KRW) and Revenue by Segment (%)

MetricFY2021FY2022FY2023FY2024FY2025

Consolidated revenue (KRW 100M)

1,6352,0542,3372,7113,069

Synatura revenue (KRW 100M)

————322

Fevarozet revenue (KRW 100M)

————291

Lipid combinations, 3 products, outpatient Rx value (KRW 100M)

———378—

Synatura share of revenue (%)

————10.5

Group Entities

EntityRelationshipActivityNotes / source

Ahngook Bio Diagnostics (안국바이오진단)

Subsidiary

Diagnostics

Co-located at Gwacheon HQ (Dealsite, Jan 2025); reported as loss-making historically (Dealsite, 2021)

Ahngook Newpharm (안국뉴팜)

Subsidiary

Pharmaceutical sales/marketing

Co-located at HQ; in capital impairment in 2020 (Dealsite, 2021); former CEO is current Ahn-Gook CEO Park In-cheol

Bix Bio (빅스바이오)

Subsidiary (as of 2021)

Not detailed

—

Medifer (메디페르)

Subsidiary (as of 2021)

Not detailed

—

Ahngook Health (안국건강)

Affiliate (29.98% held as of 2021)

Health functional foods (lutein, eye health)

Controlled by Eo Gwang (54.44%); FY2020 revenue KRW 53.8bn, operating profit KRW 4.2bn (Dealsite, 2021)

MustBio (머스트바이오)

Related investee / affiliate

Immuno-oncology biologics

Founded by former Ahn-Gook VP and R&D head Kim Maeng-seop; co-development deal with Celltrion, 2025 (Dailypharm, 5 Nov 2025)

Mirae Asset–Ahn-Gook New Growth Investment Partnership No.1

65% interest (KRW 13.0bn of KRW 20bn)

Venture fund (bio, medical devices)

Managed by Mirae Asset Capital (Digital Today, 31 Oct 2025)

Income Statement (KRW) and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW 100M)

1,6352,0542,3372,7113,069

Revenue growth YoY (%)

14.025.613.816.013.2

Operating income (KRW 100M)

-1197516798

Net income (KRW 100M)

37691016373

Dividend per share (KRW)

220220220440—

Margin metric (%)

Margin metric (%)FY2021FY2022FY2023FY2024FY2025

Operating margin (%)

-0.74.72.22.53.2

Net margin (%)

2.33.40.46.02.4

Income Statement (KRW) and Margin Analysis (%) (Quarterly)

MetricQ4 2024Q1 2025Q2 2025Q3 2025Q4 2025 (implied)Q1 2026Q2 2026

Revenue (KRW 100M)

707758768777766989919

Operating income (KRW 100M)

12595049-6016086

Net income (KRW 100M)

-7353134-2712486

Operating margin (%)

1.77.86.56.3-7.816.29.4

Balance Sheet (KRW)

MetricFY2024FY2025

Total assets (KRW 100M)

3,025.4—

Total equity (KRW 100M)

—1,662.9

Returns & Leverage Ratios (KRW)

MetricFY2024

Proceeds from HQ disposal (KRW 100M)

220

Returns & Leverage Ratios (%)

RatioFY2025

ROE (%)

4.4

Revenue by Region (KRW)

RegionFY2023FY2024FY2025

Consolidated total (KRW 100M)

2,3372,7113,069

Valuation Snapshot

MetricValueDate / source

Recent price

KRW 10,160 (Butler.works reading); KRW 10,550 (Stockhub, 8 Jul 2026)

—

52-week range

KRW 7,280 – KRW 12,730

Stockhub, Jul 2026

1-week / 1-month / 2-month / 6-month / 1-year return

−14.05% / −6.31% / +35.38% / +25.2% / +44.25%

MarketInOut, as of 20 Aug 2026

Notable move

Daily limit-up on Q1 2026 results day (14 May 2026)

Dailypharm

Reference point

High-KRW-7,000s in Aug 2025

Dealsite, 20 Aug 2025

Valuation Multiples

MultipleAhn-Gook (Butler.works)Ahn-Gook (MarketInOut, 20 Aug 2026)Ahn-Gook (Stockhub, Jul 2026)Peer reference

P/E (x)

6.127.548.36—

P/B (x)

0.74—0.70—

EV/EBITDA (x)

—4.34——

EV/EBIT (x)

—6.13——

EV/Sales (x)

—0.40——

Dividend yield (%)

6.23——

Ranked #1 by FY2025 yield among 70 pharma/bio payers (~7%)

Derived TTM P/E at KRW 10,160 (net income ≈ KRW 21.7bn, ≈ 11.4M shares outstanding ex-treasury)

≈ 5.3 (derived)

———

Per-Share Data and Returns & Leverage Ratios (%)

MetricFY2021FY2022FY2023FY2024FY2025

Dividend per share (KRW)

220220220440—

Market dividend yield (%)

———6.67.0

Analyst Conclusions

Management guidance

There is no formal annual guidance. The stated ambition is KRW 500bn revenue and a UBIST top-10 ranking by 2030 (CEO Park In-cheol, Jan 2026). That implies roughly a 10% revenue CAGR from FY2025's KRW 306.9bn, a pace that H1 2026 (+25%) is comfortably exceeding.

Consensus expectations

There is no sell-side consensus. A simple run-rate gives FY2026 revenue of about KRW 380bn (H1 2026 of KRW 190.8bn × 2) before seasonality. Respiratory demand is typically stronger in H2/Q4, but the company has historically booked year-end charges. This is an analyst illustration, not guidance.

Bull case

  1. Structural margin uplift. Mix shift to self-manufactured Fevarozet plus CMO volumes lifted the operating margin from 3.2% (FY2025) to 12.9% (H1 2026, derived). Sustaining even 10% on about KRW 350bn of revenue would roughly quadruple FY2025 operating profit.

  2. Multiple growth vectors in place. The 1/10 mg Fevarozet strength, Widaplik's first-line triple combination, a dedicated liquid plant (2027) and H&B multichannel expansion each extend the runway beyond Synatura.

  3. Deep-value entry with high yield. P/B of about 0.7, P/E of about 5–8x and a yield of about 6–7%. Treasury-share cancellation or further dividend increases could catalyse a re-rating.

Bear case

  1. Owner legal tail risk. A conviction in the long-running rebate case could trigger reimbursement suspensions or price penalties on implicated products, and destabilise the co-CEO governance model.

  2. Manufacturing compliance. The May–June 2026 tablet suspension hit the line that produces about 68% of parent revenue. A repeat violation would escalate penalties and could cost CMO customers.

  3. Commoditisation. Pitavastatin/ezetimibe is crowding with low-dose generics, and price reform and PVA cuts could compress Fevarozet's economics just as the company commits about 29% of equity to capex.

Key catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timingWhy it matters
Q3 2026 quarterly reportMid-Nov 2026Tests margin durability after the Q2 normalisation and the suspension period
FY2026 preliminary results and DPS decisionFeb–Mar 2027Dividend trajectory; Q4 charge pattern
Verdict in the Eo Jin rebate case and any administrative sanctionsUnscheduledLargest single governance risk
Widaplik Korean clinical / MFDS milestones2026–2027New cardiovascular growth leg
Fevarozet 1/10 mg uptake and UBIST share vs LivalozetMonthly UBIST dataCore franchise health
Drug-price reform implementation2026–2027Sector-wide earnings risk
Hyangnam expansion and liquid-plant progressThrough 2027–2028Capex discipline; capacity for growth
Treasury-share actions / Commercial Act reform2026–2027Potential re-rating catalyst
Identity of 5%+ holders behind 2026 large-holding filingsOngoingShareholder-base changes
Mirae Asset fund deployments; MustBio–Celltrion progressOngoingOption value

Concluding analyst verdict

Ahn-Gook Pharmaceutical has completed an unglamorous but genuine turnaround. In 2020 it was a shrinking, owner-tainted generic house losing in-licensed brands. By 2026 it had a KRW 300bn-plus franchise whose growth comes from a product it developed, manufactures and supplies to most of its competitors. The 2026 earnings inflection, a 16% operating margin in Q1 and about 13% for H1, is the first evidence that scale and mix can lift a business that spent most of the past five years earning 2–5% margins. Fevarozet's leadership among followers, the toll-manufacturing position and a sensible pipeline of licensed and line-extension assets give the 2030 KRW 500bn target credibility. The current trajectory is already ahead of what that target requires.

The equity case, however, is not primarily operational. The market prices the stock below book and at mid-single-digit earnings multiples. That discount reflects three linked issues: governance (a controlling shareholder with a criminal conviction under appeal and a separate rebate trial pending for over six years), compliance (a recent GMP suspension on the core tablet line) and transparency (Korean-only filings, no investor communication, no sell-side coverage). The high dividend yield and unused 12.86% treasury block give patient holders a tangible return while those risks resolve.

On balance, Ahn-Gook screens as a fundamentally improving, governance-discounted value situation. The key swing factors are the rebate-case outcome and any associated reimbursement sanctions, proof that the post-suspension quality system holds, and whether the 2026 margin step-up survives the drug-price reform cycle. If all three resolve favourably, a re-rating toward book value and sector-average multiples is plausible. An adverse verdict with reimbursement penalties is the principal path to permanent impairment. Investors should obtain the DART filings directly for balance-sheet, cash-flow and related-party detail, which accessible secondary sources do not fully reproduce.


Sources referenced (by publisher): DART filings as transcribed by Butler.works, ETFshopping, MarketInOut, Stockhub, financialfilings.com and NICE/Catch.co.kr; Dailypharm (2019–2026); Medical Times (2018–2026); Dealsite (2019–2026); The Fact (2022–2024); Ajunews (Sep 2023); NewDaily (May 2025, May 2026); Medipharmhealth (Jul 2026); Digital Today (Oct 2025); Bizwatch (2019, Feb 2026); Dailian (Oct 2026); Opensurvey (2026); Daum/Hankyung (Apr 2026); Yahoo Finance, Morningstar, Simply Wall St, CB Insights, PatSnap, Fundable, Jobplanet (company profiles); Biospectator; Getcha; News Tomato.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior rolesAge / born

Park In-cheol (박인철)

President & Representative Director (CEO)

Co-CEO from 2 Jan 2025; named sole representative in 2026 coverage

Head of Pharmaceutical Division; Head of Marketing; CEO of subsidiary Ahngook Newpharm. Credited with data-driven and digital marketing strategy

—

Eo Jin (어진)

Vice Chairman; inside director; largest shareholder

CEO 1998–Mar 2022; inside director from Jan 2023; co-CEO from Nov 2024 (current representative status unconfirmed)

Second-generation owner

Born 1964 (Yahoo Finance)

Won Deok-kwon (원덕권)

Former President & CEO

Sole CEO from Mar 2022; representative term expired 29 Mar 2025

First professional CEO in company history

—

Chang-Gyun Han (한창균)

Executive officer and director

——

Born 1963 (Yahoo Finance)

Lee Seung-han (이승한)

Head of Legal

—

Testified at the National Assembly audit and apologised for past sales practices

—

“—” = not publicly disclosed.

Governance Overview

ItemDetail

Independent (outside) directors

At least one outside director present at the 31 Oct 2025 board meeting (Digital Today); number not disclosed

Audit function

Statutory auditor (감사) attended the 31 Oct 2025 meeting, indicating an auditor rather than an audit committee, consistent with KOSDAQ companies under KRW 2 trillion in assets

Chair/CEO separation

Not disclosed. Historically the controlling family held both roles; the 2022–2024 professional-CEO period separated ownership from management

Compliance systems

ISO 37001 and ISO 37301 certified since Dec 2021; compliance programme (CP) rules established; ESG management introduced (Dailypharm column)

Board & Management Changes

DateChangeContext

Mar 2022

Eo Jin resigns as CEO on health grounds; Won Deok-kwon becomes sole CEO

Widely read as distancing the company from owner legal risk (The Fact)

27 Jan 2023

Eo Jin returns as inside director

Company said he would not serve as CEO or be involved in management (The Fact, Dec 2022)

Nov 2024

Eo Jin appointed co-CEO

Return to front-line management (Dealsite)

2 Jan 2025

Eo Jin / Park In-cheol co-representative system

Sales and marketing strengthening (Dailypharm)

29 Mar 2025

Won Deok-kwon's representative term expires

Dealsite (Dec 2024) linked his tenure to the outcome of Eo Jin's trial

Feb 2025

R&D and production organisation restructured

Dailypharm, 7 Feb 2025

Major Shareholders

HolderStake (%)Basis

Eo Jin and related parties (largest-shareholder group)

48.22

31 Dec 2025 (ETFshopping/DART); down from 49.75% at end-2021

Treasury shares

12.86

Butler.works

Minority shareholders (8,420 holders)

37.64

31 Dec 2025 (DART)

Other / 5%+ holders

Not separately identified

Large-holding reports (주식등의대량보유상황보고서) were filed on 5 Jun, 30 Jun and 11 Sep 2026; filers not identified in sources reviewed

Competitive Landscape

Competitors by Segment

SegmentCompetitorOverlapping product(s)Relative positioningSource / basis

Pitavastatin/ezetimibe

JW Pharmaceutical

Livalo, Livalozet (originator)

Market creator and leader in the combination; much larger company

Medical Times; Dealsite

Pitavastatin/ezetimibe

Daewon Pharmaceutical

Tabarozet (KRW 18.2bn outpatient Rx vs Fevarozet KRW 29.2bn)

Second-largest follower; manufactured by Ahn-Gook

Medical Times, Mar 2026

Pitavastatin/ezetimibe

Boryung

Pitavastatin/ezetimibe combination (Ahn-Gook-made)

Partner-competitor

Dailypharm

Pitavastatin/ezetimibe

Dongkwang Pharmaceutical

Combination (Ahn-Gook-made)

Partner-competitor

Dailypharm

Pitavastatin/ezetimibe

Hanlim Pharm

Combination, including early 1/10 mg

Partner-competitor; low-dose first mover

Dailypharm, Apr 2026

Pitavastatin/ezetimibe low dose

Ilsung IS

First 1/10 mg generic (Jan 2026)

Low-dose pioneer

Dailypharm, Apr 2026

Pitavastatin/ezetimibe low dose

Daewoong Pharmaceutical

1/10 mg generic

Large-company entrant

Dailypharm

Pitavastatin/ezetimibe low dose

Ildong Pharmaceutical

1/10 mg generic

Entrant

Dailypharm

Rosuvastatin/ezetimibe & hypertension

Large domestic players (e.g., Hanmi, Chong Kun Dang, Yuhan)

Rosuvastatin/ezetimibe and ARB/CCB combinations

Larger scale and field forces

General industry knowledge; no figures verified here

Respiratory (cough/sputum)

Domestic OTC/ETC respiratory brands (e.g., Hanmi's pelargonium syrup, Daewon's cough products)

Botanical and synthetic antitussives / expectorants

Synatura is a leading botanical prescription syrup; competitive shares not disclosed

General industry knowledge; no figures verified here

Mid-tier generic peers

Kukje Pharmaceutical

Broad generics, ophthalmics

Smaller peer (FY2024 revenue KRW 156.5bn)

Dailypharm, Mar 2025

Mid-tier generic peers

Samjin Pharmaceutical

Cardiovascular, analgesics

Similar mid-tier peer; operating profit down 15% in FY2025

Bizwatch, Feb 2026

Health functional foods

Chong Kun Dang Health, Daewoong, Ilyang, Dongkook, Donghwa and others in Daiso/Olive Young

HFF

Crowded: 22 pharma companies sell HFF at Daiso in 2026, up from 3, with about 160 items, up from about 30

Dailian, 5 Oct 2026

Peer Comparison FY2024

MetricAhn-GookJW PharmaceuticalKukje Pharmaceutical (FY2024)

Revenue (KRW 100M)

3,0697,7481,565

Revenue growth YoY (%)

13.27.7—

Operating income (KRW 100M)

9893667

Operating margin (%)

3.212.14.3

Net income (KRW 100M)

7361752

Company Snapshot

424

Employees

1959

Founded

Gwacheon, South Korea

Headquarters

SWOT Analysis

Strengths

  • Accelerating earnings power. Q1 2026 operating profit of KRW 16.0bn exceeded FY2025's full-year KRW 9.8bn, with a 16.2% margin vs 7.7% a year earlier (Q1 2026 report via Dailypharm).
  • Market-leading follower brand. Fevarozet reached KRW 29.1bn in FY2025 and grew 118% from January to December 2025, vs 34% for originator Livalozet (Dailypharm, 5 Feb 2026).
  • CMO platform. Ahn-Gook manufactures all pitavastatin/ezetimibe combinations except Livalozet, so it monetises competitor growth (Dailypharm, Feb 2026).
  • Consistent top-line growth. Four consecutive revenue records, reaching KRW 306.9bn in FY2025, a 17.0% CAGR since FY2021 (Butler.works).
  • Shareholder-friendly capital return. DPS doubled to KRW 440 for FY2024; FY2025 dividend yield of about 7% was the highest among 70 Korean pharma/bio payers (Medical Times; Dailypharm, 20 Mar 2026).
  • Modern consolidated infrastructure. Unified Gwacheon HQ and R&D Center (about 3,740 m², three times the former labs); all sites ISO 14001/45001-certified (Medical Times, Sep 2024; Dailypharm, Jun 2026).

Weaknesses

  • Thin historical margins. Operating margin was 2.2–4.7% in FY2022–FY2025, and Q4 2025 implied an operating loss of about KRW 6.0bn (derived from DART quarterly data).
  • Low R&D intensity. R&D fell to the 5% range of revenue by FY2023 (Dealsite, Apr 2024), limiting proprietary pipeline value.
  • Concentration. Fevarozet and Synatura together are about 20% of Q1 2026 revenue (11.3% + 8.3%), and tablets are 68.1% of parent revenue (NewDaily).
  • Compliance track record. Shuvazet sales suspension (2021), unapproved-trial conviction (2022) and the tablet manufacturing suspension (2026) (Dailypharm; The Fact; Medipharmhealth).
  • Negligible international footprint. Exports declining (Dealsite, 2024); US and China deals terminated pre-2019.
  • Opaque disclosure. Korean-only filings, no investor presentations, zero sell-side coverage (Stockhub: 0 reports).

Opportunities

  • Low-dose and line extensions. The 1/10 mg Fevarozet strength targets patients moving to lower statin doses and lifts CMO volumes (Dailypharm, 22 Apr 2026).
  • Widaplik. The first FDA-approved first-line triple antihypertensive combination, with Lancet/JACC evidence (Dailypharm, 12 Mar 2026).
  • Liquid-formulation capacity. The dedicated 14,901 m² plant (Oct 2027) addresses rising liquid demand (Medical Times, Sep 2026).
  • H&B growth. Olive Young HFF sales rose 43% YoY, and the HFF market is about KRW 6 trillion (Brunch/Opensurvey; Hankyung).
  • External innovation. The KRW 20bn Mirae Asset fund and the MustBio–Celltrion partnership provide option value (Digital Today; Dailypharm).
  • Valuation re-rating. P/B of 0.70–0.74 and P/E of 6–8x, plus potential treasury-share cancellation under Commercial Act reform (Butler.works; Stockhub; Dealsite, Aug 2025).

Threats

  • Owner criminal proceedings. Eo Jin was indicted in July 2019 over about KRW 8.9bn of rebates to 85 physicians. Pre-2021 rebates can trigger reimbursement suspension, and MFDS can impose sales suspensions (The Fact).
  • GMP enforcement. A repeat violation could lengthen suspensions on the tablet line that drives growth (Medipharmhealth; NewDaily).
  • Generic crowding. Ilsung IS, Daewoong, Ildong and Hanlim launched 1/10 mg combinations before Ahn-Gook (Dailypharm, Apr 2026).
  • Drug-price reform. Government pricing changes and PVA cuts on high-volume products (Dailypharm, Dec 2025–Mar 2026).
  • Respiratory normalisation. Synatura prescriptions declined in 2025 on the pandemic/endemic base effect (Dailypharm, Feb 2026).
  • Capex execution. The KRW 48.48bn programme equals 29.15% of equity (Dailypharm, 14 Jul 2026).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
14 May 2025Q1 2025: revenue KRW 75.8bn (+15.2%), operating profit KRW 5.9bn (+91.2%) ETFshopping (DART)Confirms margin recovery trend
May 2025Reported to be negotiating HFF entry into Daiso NewDaily, 7 May 2025Start of the H&B channel push
14 Aug 2025H1 2025: revenue KRW 152.6bn (+14.7%), operating profit KRW 10.8bn (+127.8%) Medical Times; DailypharmSets up the KRW 300bn milestone
20 Aug 2025Press scrutiny of unused treasury shares (12.86%) amid Commercial Act reform proposals to mandate cancellation; share price in the high-KRW-7,000s DealsitePotential governance catalyst
16–17 Oct 2025Board calls EGM to convert capital reserve into retained earnings Medical TimesExpands dividend capacity
26 Oct 2025EGM held (approval of reserve transfer reported) Medical Times; DailypharmShareholder-return execution
31 Oct 2025KRW 13.0bn commitment for 65% of the KRW 20bn Mirae Asset–Ahn-Gook fund Digital TodayExternal innovation sourcing
Late 2025Affiliate MustBio signs immuno-oncology co-development with Celltrion Dailypharm, 5 Nov 2025Indirect pipeline validation
14 Nov 2025Q3 2025: revenue KRW 77.7bn (+15.1%), operating profit KRW 4.9bn (+590%) ETFshopping (DART)Continued growth
Dec 2025Fevarozet monthly sales exceed KRW 3.4bn Dailypharm, 5 Feb 2026Becoming the flagship brand
24 Dec 2025Industry body calls for deferral and full review of government drug-price reform DailypharmSector-wide pricing headwind
19 Jan 2026CEO interview: KRW 500bn revenue and UBIST top-10 by 2030 DailypharmFormal medium-term ambition
5 Feb 2026Fevarozet FY2025 sales of KRW 29.1bn disclosed; new strengths planned DailypharmProduct momentum
Feb 2026FY2025 revenue crosses KRW 300bn (fourth consecutive record) Dailypharm, 26 Feb 2026Scale milestone
12 Mar 2026Widaplik exclusive Korean licence DailypharmPipeline / portfolio addition
18–19 Mar 2026FY2025 business report: Synatura KRW 32.2bn (10.5%); net income lower on base effect Medical TimesMix shift confirmed
20 Mar 2026Ranked first by FY2025 dividend yield (~7%) among 70 pharma/bio payers DailypharmIncome-investor appeal
20–22 Apr 2026Fevarozet 1/10 mg approved (about a month after Livalozet's low-dose approval) Dailypharm; Medical TimesDefends leadership in the low-dose trend
14 May 2026Q1 2026: revenue KRW 98.9bn (+30.6%), operating profit KRW 16.0bn (+173.5%), net income KRW 12.4bn; shares hit the daily limit-up Dailypharm; Medical TimesEarnings inflection
15 May 2026Fevarozet overtakes Synatura as the largest product; tablet manufacturing suspension highlighted NewDailyConcentration and compliance focus
22 May–5 Jun 2026MFDS 15-day tablet manufacturing suspension for non-compliance with manufacturing/quality standards as a contract manufacturer Medipharmhealth, 15 Jul 2026Operational and compliance risk materialised
5 Jun 2026Large-holding status report filed Butler.works filings listPossible change in a 5%+ holder
25 Jun 2026ISO 14001 / ISO 45001 surveillance audits passed at all sites DailypharmEHS assurance
30 Jun 2026Second large-holding status report filed Butler.works filings listOwnership movement
14 Jul 2026KRW 48.48bn Hyangnam plant expansion approved DailypharmMajor capacity investment
28 Jul 2026Industry roundup confirms the investment period to end-Aug 2028; attributes improvement to ETC + H&B growth DailypharmContext
14 Aug 2026H1 2026 report: Q2 revenue KRW 91.9bn, operating profit KRW 8.6bn, net income KRW 8.6bn ETFshopping (DART)Sustained profitability
20 Aug 2026Shares +44% over one year; −14% over the preceding week MarketInOutVolatility after the re-rating
10 Sep 2026Groundbreaking of the dedicated oral-liquid plant Medical Times, 14 Sep 2026Capacity build
11 Sep 2026Third large-holding status report filed Butler.works filings listOwnership movement

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Segment (KRW): Consolidated revenue rose from KRW 1,635 in FY2021 to KRW 3,069 in FY2025.
Ahn-Gook Pharmaceutical Co., Ltd. — Revenue by Segment (KRW)
Series (KRW)FY2021FY2022FY2023FY2024FY2025
Consolidated revenue1,6352,0542,3372,7113,069
Synatura revenue————322
Fevarozet revenue————291
Lipid combinations, 3 products, outpatient Rx value———378—

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.